Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Samsung Biologics shells US$2.3 bln to complete acquisition of Samsung Bioepis | HealthCare Middle East & Africa Magazine
Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
SAMSUNG BIOEPIS
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar | Business Wire
Samsung Bioepis starts selling Byooviz in U.S.
Samsung Bioepis says its trastuzumab biosimilar as safe, effective as original
SAMSUNG BIOEPIS
Samsung Biologics: Inclusion of Samsung Bioepis to Boost Earnings - Businesskorea
Samsung Bioepis begins late stage clinical trial of ustekinumab biosimilar
Biogen of US might reap W2tr from Samsung Bioepis call option
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China | Business Wire
Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea | Be Korea-savvy
Samsung Bioepis - Crunchbase Company Profile & Funding
Samsung Biologics - Wikipedia
Samsung Bioepis biosimilars sales in Europe fall 6.3% in Q1 - Pulse by Maeil Business News Korea
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
Mundipharma to commercialize Samsung Bioepis to biosimilars Into Hong
Un medicament biosimilar al Enbrel dezvoltat de Samsung Bioepis a fost aprobat în SUA - 360medical.ro
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Biogen to sell equity stake in Samsung Bioepis joint venture for up to $2.3B - Drug Discovery and Development
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan
